Translating Evidence-Based Research into Value-Based Decisions in Oncology

Published Online: Tuesday, November 20, 2012
Follow Pharmacy_Times:
At a meeting hosted by the American Journal of Managed Care, key figures in the managed care industry discussed innovative payment models being utilized by payers and providers.
On Friday, November 16, 2012, the American Journal of Managed Care hosted its first annual live meeting, “Translating Evidence-Based Research into Value-Based Decisions in Oncology.” The meeting, which brought together stakeholders from all sides of the managed care industry, provided an arena for health care professionals to discuss new, innovative payment models being utilized by both payers and providers.
 
To view highlights from the meeting, click here.

Related Articles
The FDA has granted priority review status to Amgen’s supplemental New Drug Application for its carfilzomib (Kyprolis) cancer therapy.
Teikoku Pharma USA has submitted a New Drug Application to the FDA for the product.
Cancer drug prices have increased 10% each year since 1995, even after adjusting for inflation and incremental health benefits.
Cyramza, manufactured by Eli Lilly and Company, is an angiogenesis inhibitor indicated for the treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after treatment with prior fluoropyrimidine- or platinum-containing chemotherapy.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$